Cargando…

Fixed-Dose Factor Eight Inhibitor Bypassing Activity (FEIBA) in the Management of Warfarin-Associated Coagulopathies

This retrospective review evaluated our institutions’ practice of administering low fixed-dose FEIBA (high (1000 units) or low dose (500 units) for an INR ≥ 5 or <5, respectively) for the management of warfarin-associated coagulopathies. The primary outcome was the percentage of patients who had...

Descripción completa

Detalles Bibliográficos
Autores principales: Ibarra, Francisco, Cruz, Mallory, Ford, Matthew, Wu, Meng-Jou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149897/
https://www.ncbi.nlm.nih.gov/pubmed/35645329
http://dx.doi.org/10.3390/pharmacy10030050
_version_ 1784717303629217792
author Ibarra, Francisco
Cruz, Mallory
Ford, Matthew
Wu, Meng-Jou
author_facet Ibarra, Francisco
Cruz, Mallory
Ford, Matthew
Wu, Meng-Jou
author_sort Ibarra, Francisco
collection PubMed
description This retrospective review evaluated our institutions’ practice of administering low fixed-dose FEIBA (high (1000 units) or low dose (500 units) for an INR ≥ 5 or <5, respectively) for the management of warfarin-associated coagulopathies. The primary outcome was the percentage of patients who had a post-FEIBA INR ≤ 1.5. In the total population, 55.6% (10/18) of patients achieved a post-FEIBA INR ≤ 1.5. In the subgroup analysis, significantly more patients in the low dose FEIBA group achieved a post-FEIBA INR ≤ 1.5 compared to the high dose FEIBA group (71.4% vs. 45.5%, respectively, p < 0.001). In the post hoc analysis, there was a significant difference in the number of patients who achieved a post-FEIBA INR ≤ 1.5 when comparing those who received high dose FEIBA with a baseline INR 5–9.9 to those who received high dose FEIBA with a baseline INR ≥ 10 (60% vs. 33.3%, respectively, p < 0.001). The existing literature and our findings suggest that patients who present with lower baseline INR values and receive additional reversal agents are more likely to meet post-reversal INR goals. Current low fixed-dose protocols may be oversimplified and may need to be revised to provide larger fixed-doses.
format Online
Article
Text
id pubmed-9149897
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91498972022-05-31 Fixed-Dose Factor Eight Inhibitor Bypassing Activity (FEIBA) in the Management of Warfarin-Associated Coagulopathies Ibarra, Francisco Cruz, Mallory Ford, Matthew Wu, Meng-Jou Pharmacy (Basel) Study Protocol This retrospective review evaluated our institutions’ practice of administering low fixed-dose FEIBA (high (1000 units) or low dose (500 units) for an INR ≥ 5 or <5, respectively) for the management of warfarin-associated coagulopathies. The primary outcome was the percentage of patients who had a post-FEIBA INR ≤ 1.5. In the total population, 55.6% (10/18) of patients achieved a post-FEIBA INR ≤ 1.5. In the subgroup analysis, significantly more patients in the low dose FEIBA group achieved a post-FEIBA INR ≤ 1.5 compared to the high dose FEIBA group (71.4% vs. 45.5%, respectively, p < 0.001). In the post hoc analysis, there was a significant difference in the number of patients who achieved a post-FEIBA INR ≤ 1.5 when comparing those who received high dose FEIBA with a baseline INR 5–9.9 to those who received high dose FEIBA with a baseline INR ≥ 10 (60% vs. 33.3%, respectively, p < 0.001). The existing literature and our findings suggest that patients who present with lower baseline INR values and receive additional reversal agents are more likely to meet post-reversal INR goals. Current low fixed-dose protocols may be oversimplified and may need to be revised to provide larger fixed-doses. MDPI 2022-04-23 /pmc/articles/PMC9149897/ /pubmed/35645329 http://dx.doi.org/10.3390/pharmacy10030050 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Study Protocol
Ibarra, Francisco
Cruz, Mallory
Ford, Matthew
Wu, Meng-Jou
Fixed-Dose Factor Eight Inhibitor Bypassing Activity (FEIBA) in the Management of Warfarin-Associated Coagulopathies
title Fixed-Dose Factor Eight Inhibitor Bypassing Activity (FEIBA) in the Management of Warfarin-Associated Coagulopathies
title_full Fixed-Dose Factor Eight Inhibitor Bypassing Activity (FEIBA) in the Management of Warfarin-Associated Coagulopathies
title_fullStr Fixed-Dose Factor Eight Inhibitor Bypassing Activity (FEIBA) in the Management of Warfarin-Associated Coagulopathies
title_full_unstemmed Fixed-Dose Factor Eight Inhibitor Bypassing Activity (FEIBA) in the Management of Warfarin-Associated Coagulopathies
title_short Fixed-Dose Factor Eight Inhibitor Bypassing Activity (FEIBA) in the Management of Warfarin-Associated Coagulopathies
title_sort fixed-dose factor eight inhibitor bypassing activity (feiba) in the management of warfarin-associated coagulopathies
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149897/
https://www.ncbi.nlm.nih.gov/pubmed/35645329
http://dx.doi.org/10.3390/pharmacy10030050
work_keys_str_mv AT ibarrafrancisco fixeddosefactoreightinhibitorbypassingactivityfeibainthemanagementofwarfarinassociatedcoagulopathies
AT cruzmallory fixeddosefactoreightinhibitorbypassingactivityfeibainthemanagementofwarfarinassociatedcoagulopathies
AT fordmatthew fixeddosefactoreightinhibitorbypassingactivityfeibainthemanagementofwarfarinassociatedcoagulopathies
AT wumengjou fixeddosefactoreightinhibitorbypassingactivityfeibainthemanagementofwarfarinassociatedcoagulopathies